Key result
Dimethyl fumarate reverses myocardial fibrosis by blocking YAP nuclear localization and KCa3.1 expression.
Why the study?
The regulation of intermediate-conductance Ca2+-activated K+ channel (KCa3.1) expression by β-adrenergic receptor activation in myocardial fibrosis remains unclear, and the potential of dimethyl fumarate to ameliorate this fibrosis via YAP inhibition was unknown.
Does dimethyl fumarate ameliorate myocardial fibrosis induced by β-AR activation in mice models?
Does dimethyl fumarate ameliorate myocardial fibrosis induced by β-AR activation in mice models?
Dimethyl fumarate, an existing drug used for skin diseases, effectively reverses β-adrenoceptor-mediated myocardial fibrosis and cardiac dysfunction in preclinical models, suggesting translational potential for treating heart failure.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating in mouse models of established fibrosis; leaves open clinical translation of dimethyl fumarate or YAP/KCa3.1 targeting.
Background Myocardial fibrosis is a pivotal pathological component of the failing heart where the sympatho‐β‐adrenergic receptor (β‐AR) signaling is augmented. Intermediate‐conductance Ca 2+ ‐activated K + channel (K Ca 3.1) is expressed in fibroblasts and mediates fibrosis, but the regulation of K Ca 3.1 expression by β‐AR activation remains unclear. Used for treatment of skin diseases, dimethyl fumarate (DMF) is recently found to suppress transcription cofactor yes‐associated protein (YAP). Here, we examined whether DMF ameliorates myocardial fibrosis induced by β‐AR activation through inhibiting YAP‐mediated K Ca 3.1 expression in fibroblasts. Methods We used 2 mouse models of established cardiac fibrosis induced by administration of isoproterenol (30 mg/kg per d SC) for 1 week with animals studied 4 weeks afterwards, or transgenic overexpression of β 2 ‐AR (β2‐TG) exhibiting age‐related worsening of cardiac fibrosis. In both models, DMF was administered (50 mg/kg per d IP) for 4 weeks. The mechanism of DMF in regulating K Ca 3.1 expression was studied in cultured adult mouse cardiac fibroblasts exposed to isoproterenol. Results Mice subjected to repeated isoproterenol injections developed myocardial inflammation and fibrosis with irreversible cardiac dysfunction. These phenotypes seen in both models were reversed by DMF treatment in vivo. Mechanistically, in both in vivo models and in cultured fibroblasts, we observed declined YAP phosphorylation and enhanced YAP nuclear localization induced by isoproterenol, changes accompanied by upregulation of K Ca 3.1 expression at mRNA and protein levels. These changes were largely abolished by DMF treatment. Conclusions DMF reverses the established myocardial fibrosis following β‐AR activation by inhibiting YAP nuclear localization and resultant K Ca 3.1 expression in fibroblasts.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2026) studied Myocardial fibrosis. Dimethyl fumarate vs. Vehicle was evaluated on Myocardial fibrosis and cardiac dysfunction. Dimethyl fumarate reversed established myocardial fibrosis following β-adrenergic receptor activation by inhibiting YAP nuclear localization and resultant KCa3.1 expression in fibroblasts.
Synapse has enriched 10 related papers. Consider them for comparative context: